The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the ...

According to the Mayo Clinic, most weight loss occurs within the first four to five months of use. Long-term use of weight loss drugs can lead to sustained weight decreases and improvements in overall ...

Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Health-care companies rose slightly as traders bought into defensive sectors in light of uncertainty about tariff levels.

Medicare no longer covers Wegovy specifically for weight loss purposes, though coverage may still be available when ...